CheckMate-142 is designed to determine whether nivolumab alone or in combination with other anticancer drugs can yield meaningful reductions in tumor size in patients with colorectal cancer that has metastasized or recurred following at least one prior line of therapy.
The phase III CELESTIAL trial met its primary endpoint by demonstrating a survival advantage with cabozantinib in patients with advanced hepatocellular carcinoma that progressed following prior systemic therapy, as presented by Dr. Ghassan K. Abou-Alfa (pictured).
A General Session held January 20 during the 2018 Gastrointestinal Cancers Symposium provided a comprehensive overview of early-onset CRC, including results of a study focused on the age distribution of tumor gene expression in patients with stage II/III colon cancer.
Results of the randomized controlled TACTICS trial demonstrate that transcatheter arterial chemoembolization (TACE) in combination with sorafenib significantly improved progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), as compared with TACE alone.
Use of the oral fluoropyrimidine-based chemotherapy S-1 in combination with gemcitabine yielded similar efficacy and a more favorable and convenient tolerability profile versus cisplatin and gemcitabine in patients with advanced biliary tract cancer, as presented by Dr. Chigusa Morizane (pictured).
The phase III RAINFALL trial established the statistical benefit of ramucirumab added to standard chemotherapy for patients with previously untreated metastatic gastric or gastroesophageal junction adenocarcinoma. Dr. Charles S. Fuchs (pictured) presented the data.
Dr. Davendra P. S. Sohal discusses the management of metastatic pancreatic cancer, specifically the advances made since ASCO issued guidelines in 2016 for management of metastatic pancreatic cancer and the future direction for treatment.
Dr. Flavio G. Rocha reviews liver-directed therapy for advanced intrahepatic cholangiocarcinoma, which can be difficult to manage because of several factors including late diagnosis, early metastatic spread, and potential for liver dysfunction.